



Michael Bauer
CEO, Cellestia Biotech AG

Michael is a senior drug development professional with more than 20 years' experience in the life sciences industry. He has served in senior leadership positions across disciplines including clinical and preclinical drug development, project and portfolio management, regulatory affairs and metabolism research. Most recent assignments were with Novartis Oncology, as Senior Global Program Manager and Polyphor Ltd., where he served as Head of Clinical and Preclinical Development. Under his leadership, several new oncology drugs were brought into clinical development, reaching clinical proof of concept and advancing further in development towards market authorization. Michael holds a PhD in Biotechnology and an MSc in Chemistry.



Oscar A. Buset
Co-founder & CEO, Morphogene SA

Oscar is an EPFL PhD and serial entrepreneur with a track record of spinning out hightechnology/deep-science innovations from leading European universities. Oscar's 1st startup saw him spin out his own PhD thesis to create Snaketeck, an electronic design automation software company, which grew from 2 to 30 people in 4 years before merging with Simplex Solutions in 2000 and making an initial public offering on the Nasdaq in 2001. His most recent startup, Anokion, is a biotechnology company focused on immune tolerance that grew from 4 to over 50 people and is now starting clinical trials.



Sean Jiang
Founder & CEO, Yafo Capital

Mr. Jiang is Founding Partner and CEO of Shanghai Yafo Capital, investment & advisory boutique focused on the Life Sciences. He has over 20 years Wall Street experience in investment banking and direct investments in global biopharma companies. Sean held a position as Chinese General Manager of ISI Group (NY) and Managing Director of ISI Research. He was also Senior Research Analyst at Roth Capital (LA) where he was involved in several cross-border transactions. When at Xiangcai Securities, Sean was the Executive Director, responsible for advising foreign institutional investors in China's capital markets. He is CFA holder.



Michael K. Wang

**Vice President, Overseas Investment and Business Development,
China Grand Pharmaceuticals**

Michael Wang, VP for Business Development at China Grand Pharmaceutical (CGP), has been with the company and its affiliates since 2001. While implementing the key corporate development strategies of “innovation” and “going global” for the past few years, many achievements have been made, including Cardioovum & Conavi in cardiovascular areas, Sepsis program with ANU and Parainfluenza with GU in infections, Dry Eye project with BRIM in Taiwan & Pterygium project with Cloudbreak in the U.S. in ophthalmology, and very recently, an mRNA platform project with eTheRNA in Belgium in oncology and infections. Dr. Wang had a medical education, had served in GSK and other multinational companies prior to joining CGP and has over 30 years of pharmaceutical industry experiences in China.



Dr. Jean-Pierre Rosat

Managing Partner & Founder, 4FO Venture Partners

Jean-Pierre Rosat has been trained as a scientist with a PhD in Immunology. After a post-doc at Harvard Medical School, he completed his education with an MBA and has been active as an entrepreneur, co-founding more than ten Swiss companies and managing part of them as the CEO. He raised more than 150 MCHF for his ventures. Since 2016, he is a General Partner at 4FO Ventures, which he co-founded with Berger, van Berchem and Cie in Geneva. 4FO Ventures invest on early stage AI and Medtech companies in Switzerland and helps its portfolio companies to expand in China.



Moderator: Fiona Gao

**Attorney-at-law (New York), Senior Associate & Manager of China
Life Sciences Group, VISCHER AG**

Fiona focuses on cross-border transactions (foreign direct investment, M&A, corporate and commercial) and Life Sciences. She advises Swiss and international clients, in particular Chinese clients, of all sizes.

With over 10 years of multi-jurisdictional (China, Switzerland, U.S.) legal advisory experiences in leading law firms and in in-house team of multinational companies, she brings a unique and comprehensive legal expertise to Sino-Swiss clients.

Combining her legal and industry expertise, she counsels and guides Chinese and Swiss Life Sciences companies in cross-border investment and collaboration.